Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Immunitybio Inc Stock (IBRX) Moved Up by 11.15% on Sep 30: What Signal Does It Send?

Source Tradingkey

Immunitybio Inc (IBRX) moved up by 11.15%. The Pharmaceuticals & Medical Research sector is down by 0.22%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Eli Lilly and Co (LLY) up 0.07%; Moderna Inc (MRNA) down 6.56%; Bristol-Myers Squibb Co (BMY) up 0.11%.

What is driving Immunitybio Inc (IBRX)’s stock price up today?

ImmunityBio experienced a notable upward rally marked by elevated trading activity, driven by robust buying interest across the commercial-stage oncology sector. Investor optimism continues to be fueled by strong commercial momentum surrounding its flagship immunotherapy, ANKTIVA, alongside steady regulatory and pipeline progress in global jurisdictions. Continued market adoption of ANKTIVA for non-muscle invasive bladder cancer, combined with supplemental regulatory filings and expanding international approvals, has significantly reinforced long-term growth expectations among institutional and retail investors alike.

In addition to core commercial traction, sentiment has been energized by strategic corporate developments within the company's strategic ecosystem. Strategic investments and leadership engagements by Executive Chairman Dr. Patrick Soon-Shiong have highlighted potential collaborative synergies across complementary oncology platforms. Furthermore, recent high-profile executive leadership additions and global marketing authorizations have further bolstered market confidence in the management team's ability to execute its commercialization and clinical development goals.

From a market dynamics perspective, the equity demonstrated strong technical momentum as aggressive intraday buying pushed shares higher. Wall Street sell-side analysts maintain an overall bullish consensus on the stock, citing substantial top-line revenue growth potential and price targets that reflect significant upside from current levels. The convergence of underlying fundamental tailwinds, favorable analyst posture, and a strong momentum-driven technical setup provided the primary impulse for today's strong performance.

Technical Analysis of Immunitybio Inc (IBRX)

Technically, Immunitybio Inc (IBRX) shows a MACD (12,26,9) value of 0.183, indicating a buy signal. The RSI at 67.698 suggests neutral condition and the Williams %R at 10.991 suggests overbought condition. Please monitor closely.

Fundamental Analysis of Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $113.29M, ranking 74 in the industry. The net profit is $-351.40M, ranking 597 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Strong Buy, with an average price target of $12.75, a high of $15.00, and a low of $12.00.

More details about Immunitybio Inc (IBRX)

Company Specific Risks:

Widening Net Losses and Persistent Cash Burn: Despite commercial revenue growth from ANKTIVA, ImmunityBio posted a quarterly net loss of $0.22 per share, missing consensus estimates of ($0.08) by ($0.14) due to rising operational and R&D expenditures that keep trailing twelve-month free cash flow deeply negative at -$288.5 million.
Equity Dilution and Capital Overhang: ImmunityBio's ongoing capital requirements have led to repeated equity issuances, warrant executions, and reliance on related-party convertible debt, creating persistent equity dilution overhang for minority shareholders.
Concentrated Governance and Significant Insider Offloading: Executive Chairman Dr. Patrick Soon-Shiong and affiliated entities control over 64% of voting stock, limiting minority shareholder influence, while recent SEC Form 4 filings reveal major insider share sales under Rule 10b5-1 plans that drastically reduced director positions.
Binary Regulatory and Pipeline Execution Risk: The stock remains highly sensitive to binary clinical and regulatory milestones, notably the FDA's pending PDUFA target action date of January 6, 2027 for supplemental BLA approval in BCG-unresponsive papillary bladder cancer.

Source

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

October hike odds climb toward 60% as Goldman and BofA both flip — what Warsh's "dose of accommodation" really changed Rate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.

Author Irene Q.

Sep 23, Wed

Rate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.

Four jobs reports in five days: what JOLTS, ADP, claims and the September payrolls mean for the October Fed decision The US labour market faces its densest data week of the month. JOLTS job openings land Tuesday (7.2 million expected), ADP on Wednesday (70,000 expected), initial claims on Thursday and the September non-farm payrolls on Friday (100,000 expected, down from 162,000). Markets price a 64%-70% chance of another quarter-point Fed hike on October 28. The dollar index sits at 100.77 and the S&P 500 at 7,729.8.

Author Mitrade

Sep 28, Mon

The US labour market faces its densest data week of the month. JOLTS job openings land Tuesday (7.2 million expected), ADP on Wednesday (70,000 expected), initial claims on Thursday and the September non-farm payrolls on Friday (100,000 expected, down from 162,000). Markets price a 64%-70% chance of another quarter-point Fed hike on October 28. The dollar index sits at 100.77 and the S&P 500 at 7,729.8.

Nvidia's $150 billion buyback landed — and the AI sector fell anyway. That's the signal worth trading Nvidia closed up 1.68% at $228.86 on 28 September after announcing a $150 billion share repurchase authorisation, the largest single corporate buyback on record, while the rest of the AI complex sold off: AMD -3.6%, Micron -2.6%, Meta -4.8% and the Philadelphia Semiconductor Index -1.61%. The divergence is not noise. Capital is rotating toward cash-flow certainty, not abandoning the AI theme. With Micron reporting after the close on 30 September, here is what the split means.

Author Irene Q.

Sep 29, Tue

Nvidia closed up 1.68% at $228.86 on 28 September after announcing a $150 billion share repurchase authorisation, the largest single corporate buyback on record, while the rest of the AI complex sold off: AMD -3.6%, Micron -2.6%, Meta -4.8% and the Philadelphia Semiconductor Index -1.61%. The divergence is not noise. Capital is rotating toward cash-flow certainty, not abandoning the AI theme. With Micron reporting after the close on 30 September, here is what the split means.

【Daily Brief】30-year Treasury tops 5.59%, S&P 500 slips to 7,670 and gold holds $4,180 — PCE lands tonight The 30-year Treasury yield closed at 5.59%, its highest since June 2002, and the Dow fell 131.59 points to 51,349.92. US consumer confidence dropped to 81.9, a 12-year low, and JOLTS job openings fell to 7.1 million. August PCE and Q3 GDP both land at 8:30am ET tonight.

Author Suzie

Sep 30, Wed

The 30-year Treasury yield closed at 5.59%, its highest since June 2002, and the Dow fell 131.59 points to 51,349.92. US consumer confidence dropped to 81.9, a 12-year low, and JOLTS job openings fell to 7.1 million. August PCE and Q3 GDP both land at 8:30am ET tonight.

Gold falls to near $4,150 as higher Treasury yields, oil prices outweigh softer PCE inflation Gold price (XAU/USD) tumbles to near $4,150 during the early Asian session on Thursday, pressured by elevated US Treasury bond yields. Traders await the US September employment data for fresh impetus, which will be released later on Friday.

Author FXStreet

Yesterday 01: 26

Gold price (XAU/USD) tumbles to near $4,150 during the early Asian session on Thursday, pressured by elevated US Treasury bond yields. Traders await the US September employment data for fresh impetus, which will be released later on Friday.

Popular Symbols